Search

Highlights from the SWG

This SWG was established in January 2024. Highlights will be added in due course.

Read more

SWG educational activities

This SWG was established in January 2024. Educational activities will be added in due course.

Read more

EU funding approved for TOLERATE

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…

Read more

Registration & accommodation

Registration is closed

Individual RegistrationRegistration fee includes:

Access to the scientific and educational sessions of the meeting
Digital meeting materials including the program and abstract book
Networking opportunities during breaks, receptions and dinners
Catering during meeting hours incl.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

Highlights of Past EHA (HOPE) Asia 2020

EHA is returning to Sri Lanka for the 2nd edition of the Highlights of Past EHA (HOPE) Asia, organized with our hosting partner: the Sri Lanka College of Haematologists (SLCH).

Read more

Major research funding calls are out now

First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.

Read more